Critical Warnings, Restrictions And Patient Protection

Basic Salofalk Information

• INN (International Nonproprietary Name): Mesalazine or Mesalamine (5‑aminosalicylic acid, 5‑ASA).
• Brand Names Available In United Kingdom: Asacol, Pentasa, Mezavant (Lialda in some markets), Salofalk, Rowasa.
• ATC Code: A07EC02.
• Forms & Dosages: Delayed‑release tablets 400 mg and 800 mg (Asacol), rectal enemas and suppositories (brand dependent), granules and modified‑release preparations; typical packaging in blisters or bottles of 30/60/90 tablets.
• Manufacturers In United Kingdom: Not specified.
• Registration Status In United Kingdom: Mesalazine products such as Asacol are registered and available in the EU/EEA and the UK market for mild‑to‑moderate ulcerative colitis; local product information should be checked for specifics.
• OTC / Rx Classification: Prescription only (POM) in the United Kingdom and other jurisdictions covered by the product information.

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Salofalk (mesalazine) is a prescription‑only medicine and must be started and reviewed by a clinician.

• Absolute Contraindications: Known allergy to mesalazine, aspirin, sulfasalazine or other salicylates, and severe renal impairment.
• Renal Monitoring: Check renal function before starting therapy and monitor periodically during treatment.
• Elderly Patients: Start at the lowest effective dose and review more frequently because of higher risk of renal decline.
• Pregnancy And Breastfeeding: Use only where a clinician judges the benefit outweighs the risk and monitor neonates for diarrhoea if exposed through breastfeeding.
• Chronic Illness: In patients with existing kidney or liver disease, use with caution and ensure baseline blood tests are documented.

Checklist For Prescribers And Pharmacists: Confirm recent renal function (creatinine), review allergy history (aspirin/sulfasalates), check pregnancy/breastfeeding status, and review concurrent medicines for nephrotoxic or interacting drugs.

Interaction With Activities (Driving, Workplace Safety)

• Mesalazine can rarely cause dizziness or fatigue.
• Advise patients not to drive or operate heavy machinery if they feel unwell after taking it.
• Pharmacists should flag possible sedation or dizziness when counselling patients.

Under UK law, patients must stop driving if a medication or condition impairs their ability to drive and consult the DVLA guidance.

Q&A — “Can I Drive After Taking It In The Uk?”

Short answer: Generally yes, unless you experience side effects such as dizziness or severe fatigue that impair your ability.

If in doubt, do not drive and seek clinician or pharmacist advice.

Report persistent impairment to your GP and consider a Yellow Card report if you suspect an adverse reaction.

Usage Basics (What Salofalk/Mesalazine Is And Legal Status)

INN, Common Brand Names Available In The United Kingdom

Mesalazine (mesalamine, 5‑ASA) is the INN for the drug class used in ulcerative colitis.

• Asacol: Delayed‑release tablets commonly 400 mg and 800 mg.
• Salofalk: Available in tablet, granule and rectal formulations depending on market supply.
• Pentasa: Sustained‑release mesalazine.
• Mezavant (Lialda): Extended‑release preparations targeting colonic delivery.
• Rowasa: Rectal mesalazine formulations for distal disease.

Legal Classification (POM, P, GSL) — UK Context

• Mesalazine is prescription‑only (POM) in the United Kingdom and requires clinical initiation and monitoring.
• Dispensing follows NHS electronic prescriptions and community pharmacy protocols under MHRA oversight.
• Pharmacists must verify the valid prescription and counsel on monitoring requirements at handover.

Dosing Guide (Practical Regimens And Adjustments)

Standard Regimens (NHS‑Aligned)

Adjustments For Comorbidities

• Check baseline creatinine and renal function before starting mesalazine and repeat at 2–3 months after initiation, then periodically thereafter.
• Contraindicated in severe renal dysfunction; consider dose reduction or an alternative if renal function declines.
• Start elderly patients on the lowest effective dose and review renal tests more frequently.
• Use with caution in liver impairment and monitor liver function tests periodically.

Q&A — “What If I Miss A Dose?”

Take the missed dose as soon as you remember unless it is almost time for the next dose, and do not double up.

If you frequently miss doses, speak to your pharmacist or GP about adherence aids such as dosette boxes, blister packs or electronic reminders.

Interaction Chart (Food, Alcohol And Drug Interactions)

Food And Drinks

• No major dietary restrictions are required specifically for mesalazine.
• Advise moderation of alcohol during active colitis because dehydration and flares can increase complications.
• Caffeine from tea or coffee has no major evidence of altering mesalazine absorption but patients should follow what their gut tolerates.

Common Drug Conflicts And Reporting

Report suspected interactions or safety signals to the MHRA via the Yellow Card scheme.

User Reports, Trends And Patient Experience

Patients commonly report symptom relief during remission while noting a period of gastrointestinal upset when treatment starts.

• Pros: Effective induction and maintenance of remission for many patients, multiple formulations to suit disease location, rectal therapy often provides rapid relief for proctitis.
• Cons: Early side effects can include nausea, cramps, diarrhoea, headache and fatigue; adherence barriers include multiple daily dosing and tablet size.
• Practical Concerns: Some patients mention prescription charges as a barrier in England, and patients value IBD nurse support for trials of different formulations.

For balanced, reliable patient information consult NHS.uk or Patient.info and discuss any anecdotal tips from forums with your clinician before changing therapy.

Access And Purchase Options (UK Pharmacies And E‑Prescriptions)

High‑Street Chains And Online Pharmacies

• Major chains such as Boots and LloydsPharmacy commonly stock mesalazine brands subject to prescription availability.
• Several NHS‑approved online pharmacies dispense mesalazine against valid prescriptions through EPS.
• Always confirm the supplier is MHRA‑licensed and that a valid prescription is in place before purchase.

In our online pharmacy, salofalk is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

NHS E‑Prescriptions, Charges And Exemptions

Bring a valid NHS number or exemption evidence to the pharmacy when collecting a prescription.

Mechanism Of Action & Pharmacology (Simple And Clinical)

Simplified Explanation

Drug Class

Intestinal anti‑inflammatory agent acting topically on the colonic mucosa.

ATC Code

A07EC02.

Clinical Terms And Pharmacokinetics

• Mesalazine acts locally in the colon to reduce inflammation rather than relying on systemic circulation for effect.
• Delayed‑release and modified‑release formulations aim to deliver active drug to the colon and reduce systemic exposure.
• Choose formulation according to disease location: oral MR for extensive colitis, rectal enemas or suppositories for distal/proctitis disease.
• Plasma monitoring is not routine, but renal and liver function tests are required during treatment.

Indications And Off‑Label Use (MHRA And NHS Context)

MHRA‑Approved Uses

• Induction and maintenance of remission in mild‑to‑moderate ulcerative colitis.
• Treatment of proctitis and proctosigmoiditis with rectal formulations where appropriate.
• Prescribing is guided by local trust protocols and NICE recommendations.

Off‑Label Practices In NHS And Private Care

• Mesalazine is generally not recommended for Crohn’s disease due to weaker evidence of benefit.
• Rectal therapy may be used off‑label for distal proctitis in clinical practice where appropriate.
• Prescribers should document and explain any off‑label use and obtain patient consent.

Key Clinical Findings And Evidence Summary (UK/EU Perspective)

Clinical consensus supports mesalazine for induction and maintenance of remission in ulcerative colitis with multiple trial data demonstrating benefit compared with placebo for mild‑to‑moderate disease.

Head‑to‑head trials compare different formulations and doses with variable tolerability and convenience outcomes that influence choice in practice.

Clinicians should consult NICE guidance and MHRA/EMA assessments for the latest outcome data when selecting therapy.

Use of patient preference (oral versus rectal), dosing frequency and monitoring capacity should be part of shared decision making.

Alternatives Matrix (NHS Prescribing Alternatives And Pros/Cons)

Comparison Table

Pros And Cons Checklist (Practical)

• Consider dosing frequency when adherence is a concern; once‑daily MR options may help.
• Assess tolerability and previous adverse reactions when switching brands.
• Check patient age and licence for paediatric use (Asacol 400 mg licensed from age 5).
• Ensure renal monitoring arrangements are feasible for long‑term therapy.
• Consider rectal access for distal disease for quicker symptom control.
• Discuss cost and local formulary availability with the patient and pharmacy.

Common Patient Questions

• Can I take mesalazine in pregnancy? Use only if a clinician judges the benefit outweighs the risk and discuss with your obstetrician or IBD specialist.
• Will my child be able to take Asacol? Asacol 400 mg is licensed from age 5, while 800 mg formulations are generally for adults; check the product licence for paediatric dosing.
• Can I stop monitoring bloods once stable? No, periodic renal function and liver tests are advised for the duration of therapy.
• Who to contact? For dosing or side‑effect questions contact your GP, IBD nurse or community pharmacist.

NHS Cost & Access Comparison Table (How To Present)

Editors: fetch live retail prices from NHS Dispensing data or pharmacy websites before publishing because retail prices change frequently.

Registration & Regulation (MHRA, EMA, NHS Framework)

MHRA Approval And Reporting

• Mesalazine products are regulated by the MHRA and carry country‑specific product information leaflets.
• Report suspected adverse drug reactions to the MHRA via the Yellow Card scheme.
• Pharmacists should verify licence status and provide the current patient information leaflet at dispensing.

NHS Prescribing Framework

• Prescribing follows local formularies, NICE guidance and secondary care IBD pathways.
• Shared‑care agreements and electronic prescribing are commonly used for long‑term maintenance therapy.
• Document baseline tests and a monitoring plan when initiating therapy and include this in handover to primary care.

Storage, Handling And Transport (UK Household Practicalities)

Household Storage (Cold, Damp UK Climate)

• Store mesalazine between 15–30°C and protect it from moisture and direct sunlight.
• Keep in the original container or blister and away from children and pets.
• Avoid storing tablets in the bathroom in damp climates; use a bedroom or kitchen cabinet away from heat.

Home Storage Checklist: original packaging, keep below 30°C, avoid humidity, secure location away from children.

Guidance For Pharmacists And During Travel

• Advise patients to carry medication in original packaging and to keep an up‑to‑date prescription or letter for hospital admissions.
• If temperatures exceed the storage range, instruct patients to keep supplies cool and avoid direct heat.
• Provide a one‑line travel letter template: “Patient is prescribed mesalazine for ulcerative colitis; medication must be carried for personal use.”

Guidelines For Proper Use And Pharmacist Counselling (Safety‑First)

UK Pharmacist Counselling Style (What To Cover)

• Confirm the indication and planned duration of therapy with the patient.
• Review allergy history specifically for aspirin and sulfasalazine allergies.
• Ensure baseline renal function has been checked and that monitoring is scheduled.
• Explain dosing schedule clearly and provide missed‑dose instructions.
• Describe common side effects such as headache, nausea and diarrhoea, and what constitutes urgent symptoms.
• Advise when to seek urgent care: worsening colitis, chest pain, breathlessness, or signs of severe allergic reaction.
• Explain how to report side effects using the Yellow Card scheme and emphasise adherence.

Suggested counselling script line: “Take this medication as prescribed, check your blood tests as arranged, and call your IBD nurse or GP if symptoms worsen.”

NHS Patient Safety Advice

• Arrange baseline and periodic renal tests and act promptly if creatinine rises.
• Stop the medicine and seek urgent review for signs of nephritis, severe allergic reaction or marked clinical deterioration.
• Contact the IBD specialist nurse or GP for dose queries and do not switch brands or formulations without clinician input.
• Signpost patients to NHS.uk and the MHRA Yellow Card for reporting side effects.

Delivery Across United Kingdom